IMPEL NEUROPHARMA INC's ticker is IMPL and the CUSIP is 45258K109. A total of 40 filers reported holding IMPEL NEUROPHARMA INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,239 | +22434.1% | 21,485 | -26.9% | 0.00% | – |
| Q1 2023 | $41 | -100.0% | 29,401 | -7.7% | 0.00% | – |
| Q3 2022 | $155,000 | -88.5% | 31,842 | -77.9% | 0.00% | -100.0% |
| Q2 2022 | $1,344,000 | +950.0% | 144,207 | +872.6% | 0.00% | – |
| Q4 2021 | $128,000 | +1.6% | 14,827 | +43.8% | 0.00% | – |
| Q3 2021 | $126,000 | – | 10,314 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| LASRY MARC | 408,329 | $1,989,000 | 3.82% |
| venBio Partners LLC | 2,759,791 | $13,440,000 | 3.11% |
| 5AM Venture Management, LLC | 2,884,791 | $14,049,000 | 2.69% |
| Vivo Capital, LLC | 2,884,789 | $14,049,000 | 1.55% |
| DCF Advisers, LLC | 469,183 | $2,285,000 | 1.48% |
| Opaleye Management Inc. | 255,250 | $1,243,000 | 0.51% |
| Kohlberg Kravis Roberts & Co. L.P. | 4,135,971 | $20,142,000 | 0.40% |
| EPIQ PARTNERS, LLC | 18,646 | $91,000 | 0.06% |
| GILDER GAGNON HOWE & CO LLC | 142,696 | $695,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 68,300 | $333,000 | 0.01% |